Nanomedicine is an emerging field with a great potential for developing public wellbeing and economic growth. Critical issues for bringing up this potential in Europe concern especially the readiness of the economic players and their capability to effectively advance innovation from research findings towards industrial technologies and to clinical and public health applications. Industrial players need therefore to establish closer collaboration with scientific partners and with clinicians. The second issue is the ability of companies to establish multidisciplinary networks with the research and the clinical communities, increasing their efforts towards biological preclinical and clinical validations. This will bridge the gap between basic research and its application for the benefit of patients and increase the competitiveness of European actors.
Therefore EuroNanoMed targets at the creation of a mechanism to support trans-national collaborative RTD projects between academic laboratories, companies, especially SME’s, and clinical/public health actors, in the field of Nanomedicine, using a bottom up approach. Consequently, EuroNanoMed will develop coordinated Pan-European programmes based on two common joint trans-national Calls and funding of the selected projects. The themes of these two Calls will focus on the strategic research priorities of the European technology platform “Nanomedicine”: diagnostics, targeted delivery and regenerative medicine.
EuroNanoMed attains an effective critical mass: the 24 participating national/regional partners expect to dedicate significant budget to the calls, approximately 15-20% of the sum of their national/regional Nanomedicine budgets.
The Long Term Vision of EuroNanoMed is the design of a European-wide integrated programme with a coordinated funding. Potential scenario for implementation will be delivered.